[
  {
    "ts": null,
    "headline": "Are Your Mega-High Stock Dividends Safe?",
    "summary": "Tracey Ryniec, Zacks Senior Stock Strategist, and Bryan Hayes, editor of Zacks Income Investor newsletter, discuss 5 popular stocks with high dividend yields. Can the dividend be trusted?",
    "url": "https://finnhub.io/api/news?id=09c7ab26401f9bdc39f90c90c7042c41526756d09a2bca9f9ee69660eca0450e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746809040,
      "headline": "Are Your Mega-High Stock Dividends Safe?",
      "id": 134362286,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Tracey Ryniec, Zacks Senior Stock Strategist, and Bryan Hayes, editor of Zacks Income Investor newsletter, discuss 5 popular stocks with high dividend yields. Can the dividend be trusted?",
      "url": "https://finnhub.io/api/news?id=09c7ab26401f9bdc39f90c90c7042c41526756d09a2bca9f9ee69660eca0450e"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. stock underperforms Friday when compared to competitors",
    "summary": "Pfizer Inc. stock underperforms Friday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=fad867bbd3c74051cb13b19a7611cf52fa46433fe1851c47a888e769ee1b5d45",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746808560,
      "headline": "Pfizer Inc. stock underperforms Friday when compared to competitors",
      "id": 134385618,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Pfizer Inc. stock underperforms Friday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=fad867bbd3c74051cb13b19a7611cf52fa46433fe1851c47a888e769ee1b5d45"
    }
  },
  {
    "ts": null,
    "headline": "Infant hospitalizations from RSV dropped after shots became available, US data shows",
    "summary": "Infant hospitalizations due to respiratory syncytial virus infections in the United States dropped as much as 43% last year compared to previous years, following the widespread availability of...",
    "url": "https://finnhub.io/api/news?id=e64157e8560585d954cb5c8174c8bbc0f1c29195ef7d8b28b52a7d2f6fb6a4f1",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746804071,
      "headline": "Infant hospitalizations from RSV dropped after shots became available, US data shows",
      "id": 134359039,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "Infant hospitalizations due to respiratory syncytial virus infections in the United States dropped as much as 43% last year compared to previous years, following the widespread availability of...",
      "url": "https://finnhub.io/api/news?id=e64157e8560585d954cb5c8174c8bbc0f1c29195ef7d8b28b52a7d2f6fb6a4f1"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer (PFE) Just Overtook the 20-Day Moving Average",
    "summary": "Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?",
    "url": "https://finnhub.io/api/news?id=5b4c54344cf6f34393d3815eae5b746e829dced0f707fa4fe1eaa1eef8dc25d5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746798903,
      "headline": "Pfizer (PFE) Just Overtook the 20-Day Moving Average",
      "id": 134362392,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?",
      "url": "https://finnhub.io/api/news?id=5b4c54344cf6f34393d3815eae5b746e829dced0f707fa4fe1eaa1eef8dc25d5"
    }
  },
  {
    "ts": null,
    "headline": "Was Jim Cramer Right About Pfizer (PFE)?",
    "summary": "We recently published a list of 13 Stock Predictions That Jim Cramer Got Completely Wrong. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other stocks that Jim Cramer discusses. During a recent episode of Mad Money, which aired on Monday, the 5th of May, Jim Cramer gave some […]",
    "url": "https://finnhub.io/api/news?id=8c676afce3b9deaf726940920ebd249d6e943ea26a7aa72c204b33b9b9b34bae",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746793398,
      "headline": "Was Jim Cramer Right About Pfizer (PFE)?",
      "id": 134362393,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "We recently published a list of 13 Stock Predictions That Jim Cramer Got Completely Wrong. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other stocks that Jim Cramer discusses. During a recent episode of Mad Money, which aired on Monday, the 5th of May, Jim Cramer gave some […]",
      "url": "https://finnhub.io/api/news?id=8c676afce3b9deaf726940920ebd249d6e943ea26a7aa72c204b33b9b9b34bae"
    }
  },
  {
    "ts": null,
    "headline": "5 Low Price-to-Sales Stocks That Deserve a Place in Your Portfolio",
    "summary": "The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like PCB, GIII, ROCK, PFE and PAM hold promise.",
    "url": "https://finnhub.io/api/news?id=d5bc59b0cbc4c5f3ea42180413c71a940b137ef64f824fa1cc2956552dd6c902",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746792720,
      "headline": "5 Low Price-to-Sales Stocks That Deserve a Place in Your Portfolio",
      "id": 134362394,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like PCB, GIII, ROCK, PFE and PAM hold promise.",
      "url": "https://finnhub.io/api/news?id=d5bc59b0cbc4c5f3ea42180413c71a940b137ef64f824fa1cc2956552dd6c902"
    }
  },
  {
    "ts": null,
    "headline": "Metsera: A Must-Add To Your Watchlist Thanks To GLP-1 Obesity Promise",
    "summary": "Metsera is a new GLP-1 player with a Phase 2b injectable and promising oral and amylin drugs in development. Learn why MTSR stock is a hold.",
    "url": "https://finnhub.io/api/news?id=16bd0da0636aa05b8bfc8d862e8e00507956eb69509248df4b1e2fa91624563d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746783058,
      "headline": "Metsera: A Must-Add To Your Watchlist Thanks To GLP-1 Obesity Promise",
      "id": 134339290,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2189405678/image_2189405678.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Metsera is a new GLP-1 player with a Phase 2b injectable and promising oral and amylin drugs in development. Learn why MTSR stock is a hold.",
      "url": "https://finnhub.io/api/news?id=16bd0da0636aa05b8bfc8d862e8e00507956eb69509248df4b1e2fa91624563d"
    }
  },
  {
    "ts": null,
    "headline": "Hard To Imagine Retirement Income Portfolio Without These 2 Picks",
    "summary": "BDCs, REITs, MLPs & CEFs offer yield, but fall short on growth and diversification. Read about 2 picks that tackle both for income-focused investors.",
    "url": "https://finnhub.io/api/news?id=5277e773f93b325be9d0ac22ab9028df5bba20d599888d40bac39c0485924bcb",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746782100,
      "headline": "Hard To Imagine Retirement Income Portfolio Without These 2 Picks",
      "id": 134339179,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1439629580/image_1439629580.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "BDCs, REITs, MLPs & CEFs offer yield, but fall short on growth and diversification. Read about 2 picks that tackle both for income-focused investors.",
      "url": "https://finnhub.io/api/news?id=5277e773f93b325be9d0ac22ab9028df5bba20d599888d40bac39c0485924bcb"
    }
  },
  {
    "ts": null,
    "headline": "If You Invested $10K In Pfizer Stock 10 Years Ago, How Much Would You Have Now?",
    "summary": "Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the U.S. and internationally. If You Bought Pfizer Stock 10 Years Ago The company's stock traded at approximately $31.75 per share ...",
    "url": "https://finnhub.io/api/news?id=1c95d4c79598f26a7eab9d002cab8cea60e8970b5bf2bcb36e4f6cc282800779",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746756110,
      "headline": "If You Invested $10K In Pfizer Stock 10 Years Ago, How Much Would You Have Now?",
      "id": 134335931,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the U.S. and internationally. If You Bought Pfizer Stock 10 Years Ago The company's stock traded at approximately $31.75 per share ...",
      "url": "https://finnhub.io/api/news?id=1c95d4c79598f26a7eab9d002cab8cea60e8970b5bf2bcb36e4f6cc282800779"
    }
  }
]